Navigation Links
Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
Date:7/30/2008

Clinical Program Leverages Quark's RNAi Technology

FREMONT, Calif., July 30 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that its partner, Pfizer Inc, initiated patient dosing in a Phase II trial evaluating

PF-4523655 (RTP801i-14) in patients with diabetic macular edema (DME).

PF-4523655 is a novel siRNA drug candidate being co-developed by Quark and Pfizer. As part of the companies' Global Licensing Agreement, the successful commencement of the trial triggers a milestone payment to Quark from Pfizer, a small percentage of which is payable by Quark to Silence Therapeutics and Alnylam as technology license milestone payments.

The Phase II prospective, randomized, dose-ranging study is evaluating the safety and efficacy of PF-4523655 versus laser therapy in 160 DME patients at multiple centers worldwide. PF-4523655 was designed to inhibit Quark's proprietary target RTP801, a gene involved in abnormal blood vessel development and leakage in the eye. Under the companies' Global Licensing Agreement, Pfizer has exclusive development rights to siRNA-mediated therapies that inhibit RTP801 for ophthalmic and non-ophthalmic indications, while Quark is eligible for development and sales based milestone payments.

Elena Feinstein, Chief Scientific Officer of Quark, commented, "By targeting the RTP801 gene, PF-4523655 is differentiated from other therapeutics for the same ophthalmic indications. While many competitors target VEGF and its receptors, PF-4523655 inhibits abnormal blood vessel growth and leakage independently of the VEGF pathway, reduces inflammation and suppresses apoptosis. Therefore,

PF-4523655 is a siRNA therapeutic candidate with the potential to be efficacious when used as a monotherapy and in combination with existing VEGF-based therapies."

Shai Erlich, Chief Development
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
2. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
3. Quark Pharmaceuticals Appoints New Chief Medical Officer
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
8. Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million
9. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
10. Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer
11. Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial With MPI-676 in Endometriosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... ENGLEWOOD, Colo. , Sept. 22, 2014 ... one of the U.S. commercial launch of its foot ... distributed by Paragon 28.  The GORILLA TM R3CON ... 28, joining the Monster TM & Mini-Monster TM ... Systems. Comprised of 10 interchangeable subsystems, the ...
(Date:9/22/2014)... , September 22, 2014 ... has announced the addition of the  "Global ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... to wirelessly operate electronic gadgets such as ... consoles from a short line-of-sight distance. Remote ...
(Date:9/22/2014)... 22, 2014 Final shortlist ...   The second edition of the much-awaited VCCircle ... to announce the final nominations for the 2014 honours. ... the evening of September 25 at The Taj Mahal Palace, ... based on a variety of qualitative and quantitative parameters ...
Breaking Medicine Technology:Paragon 28, Inc. Launches the GORILLA(TM) R3CON PLATING SYSTEM 2Global Remotes Market 2014-2018 2Global Remotes Market 2014-2018 3Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 2Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 3
... The Pharmaceutical Care Management Association (PCMA) issued the ... hearing: "The independent drugstore lobby continues ... for themselves in Medicaid while demanding more transparency for ... and retail pharmacy allies in the embarrassing role of ...
... Oxford Finance Corporation (Oxford), a subsidiary of ... Debbie Baker to its Business Development group. As director, ... for life science and medical device companies, primarily in ... 30 years of financial experience, predominantly with the healthcare ...
Cached Medicine Technology:PCMA: Independent Drugstore Lobby Continues 'Disclosure Double Standard' Transparency Campaign 2Oxford Finance Corporation Hires Debbie Baker to Support Life Science Business Development in Western North America 2
(Date:9/22/2014)... Rockville Centre, NY (PRWEB) September 22, 2014 ... Goodwin, before whom all of the federal mesh ... Boston Scientific Corp. have been consolidated for pretrial ... re: Boston Scientific Corp. Pelvic Repair System Products ... Southern District of West Virginia; Case no. 2:12-md-02326)—requiring ...
(Date:9/22/2014)... News) -- Teens and young adults at risk for ... help prevent risky sexual behaviors, according to new recommendations ... year, about 20 million new sexually transmitted infections such ... About half involve people between 15 and 24 years ... new report, published Sept. 22 in Annals of ...
(Date:9/22/2014)... September 22, 2014 Manhattan residents who ... side of the hip , which could be bursitis ... This treatment is now offered at New York Dynamic ... called trochanteric bursitis, occurs when the trochanteric bursa becomes ... in the hip, between the iliotibial band and the ...
(Date:9/22/2014)... to 40 percent of patients undergoing breast cancer surgery ... all the cancerous tissue in the initial operation. However, ... tested a tool they developed that will help surgeons ... decreasing the chances for repeat operations. ... September 22, 2014 in the Proceedings of the ...
(Date:9/22/2014)... Hamilton, ON (September 22, 2014) South Asians living ... and double the rate of diabetes compared with while ... was published today in the Canadian Medical Association ... http://www.cmajopen.ca/content/2/3/E183.full , One of the fastest-growing ethnic ... million South Asian people living in Canada, comprising about ...
Breaking Medicine News(10 mins):Health News:Federal Court Sets Trial Date for Boston Scientific Vaginal Mesh Cases in Florida, the Rottenstein Law Group LLP Reports 2Health News:Behavioral Counseling Urged for Teens, Young Adults at Risk for STDs 2Health News:Behavioral Counseling Urged for Teens, Young Adults at Risk for STDs 3Health News:DNR Clinic Offers Hip Bursitis Treatment in Manhattan 2Health News:DNR Clinic Offers Hip Bursitis Treatment in Manhattan 3Health News:The fine line between breast cancer and normal tissues 2Health News:Higher risk of heart disease for South Asians in Canada 2
... 19 /PRNewswire-FirstCall/ - Notification of Year End,2007 Earnings Webcast ... (TSX: RBM) Year End 2007 Earnings Webcast and ... To listen to this Webcast and Conference Call ... To participate in the live conference call please dial ...
... Using the Canadian Light Source synchrotron, an international team led ... detailed structure of the enzyme the Norwalk virus uses to ... itself. The information is crucial to developing drugs that could ... viruses. , The Norwalk virus uses the enzyme, RNA ...
... (OTC,Bulletin Board: RXEI), a developer, manufacturer, and marketer of ... its,2007 year-end financial results in a conference call on ... Company will release its 2007 year-end financial results after ... call will be,RxElite CEO Jonathan Houssian, COO Earl E. ...
... ST. LOUIS, March 18 Sigma-Aldrich (Nasdaq:,SIAL) announced ... its $300 million,revolving credit facility established in December ... feature. Under the revised $450 million,revolving credit facility, ... and,$420 million will mature on December 11, 2012. ...
... The Pharmaceutical Care,Management Association (PCMA) issued the ... that are being,debated in Congress:, "PCMA ... drug,therapies is an important tool in promoting ... way with Pharmacy & Therapeutics,(P&T) committees and ...
... mental acuity may actually improve , , TUESDAY, March 18 ... treatment, head-and-neck cancer patients experience decreases in their physical ... quality of life, says a U.S. study. , ... that head and neck cancer treatment such as feeding ...
Cached Medicine News:Health News:Scientists see Norwalk virus' Achilles heel 2Health News:RxElite Inc. Fourth Quarter and Year-End 2007 Earnings Release and Conference Call Notice 2Health News:Head and Neck Cancer Outcomes a Mixed Bag 2
... The new Amsco 3080/3085 SP Bariatric ... width capacity and expanded surgical capabilities for ... extensions are rated for patients up to ... and easy attachment and full positioning capability. ...
... The new Amsco 3080/3085 SP Bariatric Foot ... capacity and expanded surgical capabilities for Amsco ... The Amsco Foot Extension is rated for ... designed for secure and easy attachment and ...
... The Pulsavac Plus System offers a ... Debridement System. High power efficiently clears bone ... Specific tips are available for hip and ... a wide range of pressure options for ...
The Simpulse Solo Pulsed Lavage System requires minimal set up and has a Wide range of tips available for every orthopaedic procedure. It uses a separate suction lumen to reduce clogging and n ergono...
Medicine Products: